227 related articles for article (PubMed ID: 24923295)
1. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.
Herold T; Metzeler KH; Vosberg S; Hartmann L; Röllig C; Stölzel F; Schneider S; Hubmann M; Zellmeier E; Ksienzyk B; Jurinovic V; Pasalic Z; Kakadia PM; Dufour A; Graf A; Krebs S; Blum H; Sauerland MC; Büchner T; Berdel WE; Woermann BJ; Bornhäuser M; Ehninger G; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
Blood; 2014 Aug; 124(8):1304-11. PubMed ID: 24923295
[TBL] [Abstract][Full Text] [Related]
2. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
[TBL] [Abstract][Full Text] [Related]
3. Trisomy 8 in acute myeloid leukemia.
Hemsing AL; Hovland R; Tsykunova G; Reikvam H
Expert Rev Hematol; 2019 Nov; 12(11):947-958. PubMed ID: 31422708
[No Abstract] [Full Text] [Related]
4. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
Herold T; Metzeler KH; Vosberg S; Hartmann L; Jurinovic V; Opatz S; Konstandin NP; Schneider S; Zellmeier E; Ksienzyk B; Graf A; Krebs S; Blum H; Cristina Sauerland M; Büchner T; Berdel WE; Wörmann BJ; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
Genes Chromosomes Cancer; 2017 Jan; 56(1):75-86. PubMed ID: 27636548
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.
Bhatnagar B; Eisfeld AK; Kohlschmidt J; Mrózek K; Nicolet D; Papaioannou D; Walker CJ; Orwick S; Blachly JS; Kolitz JE; Powell BL; Carroll AJ; Stone RM; Byrd JC; Bloomfield CD
Leukemia; 2020 Feb; 34(2):358-368. PubMed ID: 31462731
[TBL] [Abstract][Full Text] [Related]
6. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
Metzeler KH; Herold T; Rothenberg-Thurley M; Amler S; Sauerland MC; Görlich D; Schneider S; Konstandin NP; Dufour A; Bräundl K; Ksienzyk B; Zellmeier E; Hartmann L; Greif PA; Fiegl M; Subklewe M; Bohlander SK; Krug U; Faldum A; Berdel WE; Wörmann B; Büchner T; Hiddemann W; Braess J; Spiekermann K;
Blood; 2016 Aug; 128(5):686-98. PubMed ID: 27288520
[TBL] [Abstract][Full Text] [Related]
7. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.
Alpermann T; Haferlach C; Eder C; Nadarajah N; Meggendorfer M; Kern W; Haferlach T; Schnittger S
Leuk Res; 2015 Mar; 39(3):265-72. PubMed ID: 25592059
[TBL] [Abstract][Full Text] [Related]
8. Acute Myeloid Leukemia (AML): Upregulation of BAALC/MN1/MLLT11/EVI1 Gene Cluster Relate With Poor Overall Survival and a Possible Linkage With Coexpression of MYC/BCL2 Proteins.
Akhter A; Farooq F; Elyamany G; Mughal MK; Rashid-Kolvear F; Shabani-Rad MT; Street L; Mansoor A
Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):483-488. PubMed ID: 28362701
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
Garzon R; Volinia S; Papaioannou D; Nicolet D; Kohlschmidt J; Yan PS; Mrózek K; Bucci D; Carroll AJ; Baer MR; Wetzler M; Carter TH; Powell BL; Kolitz JE; Moore JO; Eisfeld AK; Blachly JS; Blum W; Caligiuri MA; Stone RM; Marcucci G; Croce CM; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18679-84. PubMed ID: 25512507
[TBL] [Abstract][Full Text] [Related]
10. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
11. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
12. Molecular and clinicopathologic characterization of AML with isolated trisomy 4.
Bains A; Lu G; Yao H; Luthra R; Medeiros LJ; Sargent RL
Am J Clin Pathol; 2012 Mar; 137(3):387-94. PubMed ID: 22338050
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gene mutation spectra in younger and older Chinese acute myeloid leukemia patients and its prognostic value.
Zhong WJ; Liu XD; Zhong LY; Li KB; Sun QX; Xu X; Wei T; Li QS; Zhu ZG
Gene; 2021 Feb; 770():145344. PubMed ID: 33333221
[TBL] [Abstract][Full Text] [Related]
14. The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia.
Yang J; Yao DM; Ma JC; Yang L; Guo H; Wen XM; Xiao GF; Qian Z; Lin J; Qian J
Tumour Biol; 2016 Aug; 37(8):10107-14. PubMed ID: 26820131
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
[TBL] [Abstract][Full Text] [Related]
16. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
17. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
20. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
